This gradual shift has raised concerns about the franchise's ability to withstand competitive pressures in the near term. Dupixent has emerged as a significant growth driver for Regeneron ...
Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback